

Polycythemia Vera: Rapid Evidence Review

Steven Fox, MD; Leslie Griffin, MD; and Dominique Robinson Harris, MD

University of Tennessee College of Medicine, Chattanooga, Tennessee

Polycythemia vera is one of three stem-cell-derived myeloid malignancies commonly known as myeloproliferative neoplasms. It is characterized by erythrocytosis, often with associated leukocytosis and thrombocytosis. It has a significant negative impact on overall mortality and morbidity in the form of arterial and venous clots, symptoms of fatigue and pruritus, and conversion to leukemia and myelofibrosis. The World Health Organization's major diagnostic criteria include an elevated hemoglobin or hematocrit level, abnormal results on bone marrow biopsy, and presence of the Janus kinase 2 genetic mutation, which is present in approximately 98% of cases. The only minor criterion is a subnormal erythropoietin level, which helps differentiate polycythemia vera from common causes of secondary erythrocytosis such as smoking, sleep apnea, and testosterone use. First-line treatments, such as low-dose aspirin and goal-directed phlebotomy to a hematocrit level of less than 45% to reduce thrombotic events, improve quality of life and prolong survival. When indicated, cytoreductive therapy, primarily with hydroxyurea, can be added with consideration of second-line agents such as pegylated interferon-alfa, busulfan, and ruxolitinib, depending on the clinical scenario. Smoking cessation and cardiometabolic disease are modifiable risk factors that should be addressed to reduce the risk of thrombosis. Currently, no medications have been shown to cure the disease or to reduce the risk of conversion to leukemia and myelofibrosis. (*Am Fam Physician*. 2021;103(11):680-687. Copyright © 2021 American Academy of Family Physicians.)

Polycythemia vera (PV) is one of three common myeloproliferative neoplasms that will likely be encountered during the career of a primary care physician.¹ This article summarizes the best, most recent evidence to guide the diagnosis and treatment of PV.

Epidemiology

- The annual incidence of PV is 0.01 to 2.61 per 100,000 people, and the prevalence is 0.49 to 46.88 per 100,000.^{2,3}
- Median age at diagnosis is 64 years (range = 19 to 95 years), and up to 25% of diagnoses occur before 50 years of age.^{4,5}

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 653.

Author disclosure: No relevant financial affiliations.

Patient information: A handout on this topic is available at <https://familydoctor.org/condition/polycythemia-vera/>.

- Nonmodifiable risk factors for PV include older age, male sex, White race, and European descent.^{2,6,7}
- Modifiable risk factors for PV include smoking, obesity, hypertension, diabetes mellitus, and hyperlipidemia.^{8,9}

Diagnosis

- Patients who have PV typically present with elevated hemoglobin and hematocrit levels found incidentally or after laboratory evaluation for patients' reported symptoms, physical examination findings, or thrombotic/bleeding events.^{5,10,11}
- The differential diagnosis of PV includes other myeloproliferative neoplasms and secondary erythrocytosis from smoking, sleep apnea, and androgen use and, rarely, erythropoietin-producing tumors (*Table 1*).¹²
- *Table 2* presents the 2016 World Health Organization's diagnostic criteria for PV.¹³ A suggested approach to evaluation is summarized in *Figure 1*.¹⁴

TABLE 1

Differential Diagnosis of Polycythemia Vera

Primary erythrocytosis

2,3-Bisphosphoglycerate deficiency
 High oxygen-affinity hemoglobin variants
 Lindau-von Hippel disease
 Other myeloproliferative neoplasms (essential thrombocytosis, primary myelofibrosis, chronic myelogenous leukemia, myelodysplastic syndrome)
 Primary familial and congenital polycythemia (*EPOR* mutation)

Secondary erythrocytosis*

Cardiopulmonary disease (chronic hypoxia, left-to-right shunt)
 Erythropoietin-producing tumors (e.g., hepatocellular carcinoma, renal cell carcinoma, hemangioblastoma, pheochromocytoma, uterine leiomyomata)
 High-altitude habitat
 Iatrogenic (testosterone, anabolic steroids, erythropoietin, blood doping)
 Renal disease (renal artery stenosis, hydronephrosis, transplant)
 Sleep apnea, obesity-hypoventilation syndrome, pickwickian syndrome
 Smoking, chronic carbon monoxide poisoning

*—Generally have elevated serum erythropoietin levels.

Information from reference 12.

TABLE 2

2016 Revised World Health Organization Diagnostic Criteria for Polycythemia Vera

Must meet all three major criteria *or* the first two major criteria and the minor criterion

Major criteria

- (1) Hemoglobin > 165 g per L (16.5 g per dL) in men or > 160 g per L (16.0 g per dL) in women
or
 Hematocrit > 49% in men or > 48% in women
or
 Increased red blood cell mass (> 25% above normal)
- (2) Bone marrow with tri-lineage proliferation with pleomorphic mature megakaryocytes*
- (3) Presence of Janus kinase 2 mutation

Minor criterion

Subnormal erythropoietin level

*—Bone marrow biopsy might not be needed in the presence of a hemoglobin level > 185 g per L (18.5 g per dL) and a hematocrit level of 55.5% in men or a hemoglobin level > 165 g per L (16.5 g per dL) and a hematocrit level of 49.5% in women.

Information from reference 13.

SIGNS AND SYMPTOMS

- *Table 3* lists the typical laboratory findings,⁵ and *Table 4* describes the frequency of the most common signs and symptoms at the time of diagnosis.^{5,10,11}
- Fatigue, insomnia, and difficulty concentrating are the most common presenting symptoms in patients with PV.¹¹

DIAGNOSTIC TESTING

- If PV is suspected after an elevated hemoglobin/hematocrit level is found, Janus kinase 2 (*JAK2*) V617F mutation and erythropoietin testing should be performed.¹²
- Bone marrow biopsy with fluorescence in situ hybridization testing and karyotyping can be helpful to confirm the diagnosis and to stratify risk.¹²


Treatment

- The goals of therapy are to improve survival and to improve quality of life by decreasing hematocrit levels, symptom burden, bleeding, and clotting complications.¹⁵
- No treatments have been shown to reduce the risk of transformation to leukemia or myelofibrosis. *Figure 2* presents a suggested approach to the treatment of PV.^{12,16,17}

PHLEBOTOMY

- All patients should receive phlebotomy with a goal hematocrit level of less than 45%.¹⁸⁻²⁰
- A randomized controlled trial of 365 patients who had PV with an average age of 65 years showed a decreased incidence of death from cardiovascular events and thrombotic events if phlebotomy was used to keep the hematocrit level at less than 45% vs. 45% to 50% over a median follow-up period of 31 months (1.1 events vs. 4.4 events per 100 person-years; number needed to treat = 30).¹⁸
- In a retrospective cohort study, 820 predominantly White patients with Medicare, a median age of 77 years, and a low rate of previous thrombosis (13%) were followed for 2.8 years. The study found that phlebotomy used a median of 2.3 times per year was associated with significantly improved survival compared with no phlebotomy (6.3 years vs. 4.5 years). The risk of thrombosis was also significantly lower with phlebotomy use (29% vs. 46%).¹⁹

FIGURE 1



JAK2 = Janus kinase 2; PV = polycythemia vera.

Algorithm for the evaluation of erythrocytosis.

Adapted with permission from *Essential Evidence Plus* and updated to reflect current diagnostic guidelines. (*Essential Evidence Plus. Polycythemia vera.* Wiley-Blackwell; 2020. Accessed November 1, 2020. <http://www.essentialevidenceplus.com>).

TABLE 4

Presenting Features of Polycythemia Vera

Symptom/finding	Percentage with finding
Fatigue	91
Insomnia	68
Pruritus on contact with water	36 to 68
Concentration problems	61
Splenomegaly	36
Erythromelalgia*	29
Arterial thrombosis	16
Venous thrombosis	7.4
Major hemorrhage	4.2

*—A state of excessive dilation of superficial blood vessels of the extremities accompanied by hyperemia, warmth, and burning pain.

Information from references 5, 10, and 11.

TABLE 3

Laboratory Findings at the Time of Polycythemia Vera Diagnosis

Finding	Value
Hemoglobin, median in g per L (range)	184 (18.4 g per dL); (151 [15.1 g per dL] to 265 [26.5 g per dL])
Hematocrit, median (range)	55% (36% to 78%)
Leukocyte count, median × 10 ⁹ per L (range)	10.4 (10,400 per μL); (3 [3,000 per μL] to 171.6 [171,600 per μL])
Platelet count, median × 10 ⁹ per L (range)	466 (466 × 10 ³ per μL); (7 [7 × 10 ³ per μL] to 2,370 [2,370 × 10 ³ per μL])
Janus kinase 2 mutation presence	98% of patients
Subnormal erythropoietin presence	81% of patients

Information from reference 5.

THROMBOPROPHYLAXIS

- All patients should receive daily low-dose aspirin (40 to 100 mg) in the absence of contraindications.^{20,21}
- A multicenter randomized controlled trial of 518 patients with a median age of 61 years showed that 100 mg of aspirin used daily over a five-year period significantly reduced the risk of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes compared with placebo (3.2% vs. 7.9%; number needed to treat = 21 over five years).²¹
- Low-dose aspirin reduces vasomotor symptoms such as headache, erythromelalgia, and pruritus in conjunction with phlebotomy.²²
- Aspirin use should be avoided in people with extreme thrombocytosis (greater than 1,000 × 10⁹ per L [1,000 × 10³ per μL]) because of increased risk of bleeding from acquired von Willebrand disease.¹⁰

CYTOREDUCTIVE THERAPY

Hydroxyurea

- Hydroxyurea is the first-line agent for cytoreductive therapy in PV.²⁰
- The previously mentioned retrospective cohort study of 820 patients with a median age of 77 years found that use of hydroxyurea was associated with significantly improved survival compared with nonusers (6.0 years vs. 5.3 years). The risk of thrombosis was significantly lower in those using hydroxyurea (27.6% vs. 45.4%).¹⁹
- A retrospective analysis of 1,042 patients followed over approximately 30 years compared use of hydroxyurea to phlebotomy only and found that fewer cardiovascular events occurred with hydroxyurea (3.0 vs. 5.8 per 100 person-years).²³
- A 2019 systematic review and meta-analysis of 3,236 high-risk patients who had PV and were treated with hydroxyurea found that the

incidence of leukemic transformation was 0.4% of persons per year, and the rate of myelofibrosis was 5.0% at five years and 33.7% at 10 years.²⁴

- Up to 24% of patients may be resistant or intolerant to hydroxyurea (*Table 5²⁵*), and common adverse effects include anemia, neutropenia, oral ulcers, skin ulcers, hyperpigmentation, and nail changes.^{1,25}
- In patients younger than 40 years, caution with hydroxyurea use is recommended because of leukemogenic concerns with long-term use.²⁶

Pegylated Interferon-Alfa

- A disease-oriented, uncontrolled study of 40 patients with high-risk PV reported that when pegylated interferon-alfa was used as first-line therapy, complete hematologic response (76% to 95%) and molecular response (18%) could be achieved over a 36-month period.²⁷ The hema-


tologic and molecular responses were defined by a hematocrit level of less than 45% in men and less than 42% in women without phlebotomy, absence of splenomegaly, normal leukocyte and platelet counts, and undetectable JAK2V617F levels.²⁷

- Up to 20% of patients discontinued the drug because of toxicity (e.g., skin toxicities possibly resulting in rash over more than 50% of body surface area or needing urgent treatment), asthenia, and hematologic abnormalities.²⁷

Busulfan (Busulfex)

- A disease-oriented, retrospective study of 19 patients with PV and a median age of 76 years who had hydroxyurea resistance or intolerance (*Table 5²⁵*) and were started on busulfan as second-line therapy reported that 75% of patients had complete or partial hematologic response over

FIGURE 2



Treatment algorithm for polycythemia vera.

Information from references 12, 16, and 17.

TABLE 5

European LeukemiaNet Definition of Resistance/Intolerance to Hydroxyurea in Patients with Polycythemia Vera

Hydroxyurea resistance	Hydroxyurea intolerance
(1) Need for phlebotomy to keep hematocrit level < 45% after 3 months of hydroxyurea (at least 2 g per day) <i>or</i> (2) Uncontrolled myeloproliferation (i.e., platelet count of 400×10^9 per L [400×10^3 per μL] and white blood cell count of 10×10^9 per L [$10,000$ per μL]) after 3 months of hydroxyurea (at least 2 g per day) <i>or</i> (3) Failure to reduce massive* splenomegaly by 50% as measured by palpation or failure to completely relieve symptoms related to splenomegaly after 3 months of hydroxyurea (at least 2 g per day)	(1) Absolute neutrophil count of 1.0×10^9 per L (1,000 per μL) or platelet count of 100×10^9 per L (100×10^3 per μL) or hemoglobin level of 100 g per L (10 g per dL) at the lowest dose of hydroxyurea required to achieve a complete or partial clinicohematologic response† <i>or</i> (2) Presence of leg ulcers or other hydroxyurea-related nonhematologic toxicities, such as mucocutaneous manifestations, gastrointestinal symptoms, pneumonitis, or fever with any dose of hydroxyurea

*—Organ extending by 10 cm from the costal margin.

†—Complete response is defined as hematocrit level of less than 45% without phlebotomy, platelet count of 400×10^9 per L, white blood cell count of 10×10^9 per L, and no disease-related symptoms. Partial response is defined as hematocrit level of less than 45% without phlebotomy or response in 3 or more of the other criteria.

Information from reference 25.

a median of 3.8 years.²⁸ Adverse effects such as cytopenias caused 15% of patients to discontinue the medication.²⁸

- Busulfan should be avoided in younger patients because of a higher association with leukemogenesis based on observational data.²⁹

Ruxolitinib (Jakafi)

- A disease-oriented, randomized trial was conducted involving patients who were hydroxyurea resistant or intolerant. In these patients, ruxolitinib achieved better hematocrit control and spleen volume improvement (decrease in volume greater than 35%) compared with other single-drug alternatives selected by the investigator, such as hydroxyurea (tolerable doses), pegylated interferon- α , pipobroman (not available in the United States), anagrelide (Agrylin), immunomodulators, or no medication (busulfan was prohibited) over a 32-week period (21% with ruxolitinib vs. 0.9% with other single-drug alternatives; $P < .001$; number needed to treat = 5).³⁰
- Immunosuppressive adverse effects made herpes zoster infection more likely (6% with ruxolitinib vs. 0% with other single-drug alternatives).³⁰

PRURITUS

- Pruritus may be present in up to 68% of patients and is severe in up to 15% of patients.¹⁰
- First-line therapy includes aspirin, antihistamines, and paroxetine (Paxil).^{22,31,32}
- Other treatment options include ruxolitinib, interferon- α , and narrow-band ultraviolet B phototherapy.³³⁻³⁵

TREATMENT IN PREGNANCY

- PV during pregnancy is rare, with a prevalence of less than 0.03 per 100,000.³⁶
- A multidisciplinary team, including an obstetrician, maternal-fetal medicine specialist, and hematologist, is recommended.³⁷
- Potentially teratogenic medications should be stopped in men and women at least three months before conception.^{36,37}
- All pregnant patients who have PV should receive low-dose aspirin, avoid iron supplementation in the absence of actual depletion, maintain gestational age-appropriate hematocrit levels, and be treated with enoxaparin (Lovenox) for six weeks postpartum if no contraindications occur.³⁶

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
All people with polycythemia vera should receive phlebotomy with a goal hematocrit level of less than 45%. ^{18,19}	B	Consistent, low-quality evidence
All people who have polycythemia vera without contraindications should take daily low-dose aspirin (40 to 100 mg). ²¹	B	Limited-quality randomized controlled trials
Hydroxyurea is considered first-line cytoreductive therapy, if indicated. ^{20,24}	B	Systematic review and meta-analysis of lower-quality studies
Patients with polycythemia vera should be counseled to stop smoking to reduce the risk of thrombosis. ³⁹	B	Systematic review and meta-analysis of cohort studies

A = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

- Interferon-alfa is the drug of choice for cytoreductive therapy if needed.³⁶

Follow-up and Monitoring

- Follow-up appointments every three to six months are recommended for routine history, physical examination, and complete blood count.¹⁵

Prognosis

- Poor prognostic features include age older than 60 years, history of thrombosis, leukocytosis, high JAK2 burden, abnormal karyotype, and established cardiovascular risk factors such as smoking, hypertension, diabetes, obesity, and hyperlipidemia.^{5,9,38}
- Smoking cessation decreases the risk of thrombosis.³⁹
- Without treatment, death typically occurs within two years, mostly from thrombotic events.⁴⁰
- Median survival of patients with PV using standard-of-care treatment, including aspirin and hydroxyurea, is 13.5 years.⁴
- For those diagnosed before 60 years of age, median survival is 24 years.⁴
- The risk of blast transformation to acute myeloid leukemia or myelodysplastic syndrome over 15 years is 5.5% to 18.7%.^{4,41}
- Progression to myelofibrosis over 15 years is 6% to 14%.^{4,41} A practical tool to calculate survival has been developed and is shown in *Table 6*.⁵

TABLE 6

Risk Factor–Based Survival Prediction in Polycythemia Vera

Risk factor	Points
≥ 67 years of age at diagnosis	5
57 to 66 years of age at diagnosis	2
Leukocyte count at presentation ≥ 15 × 10 ⁹ per L (15,000 per μL)	1
History of venous thromboembolism	1
Total: _____	
Risk group (points)	Median survival (years)
Low (0)	28
Intermediate (1 to 2)	19
High (3+)	11

Information from reference 5.

This article updates a previous article on this topic by Stuart and Viera.¹

Data Sources: We searched Essential Evidence Plus, Cochrane Database of Systematic Reviews, and PubMed with the key words polycythemia vera, myeloproliferative neoplasms, epidemiology, diagnosis, treatment, therapy, prognosis, risk stratification, management, pregnancy, randomized controlled trial, meta-analysis, systematic review,

aspirin, hydroxyurea, phlebotomy, interferon-alpha, busulfan, ruxolitinib, and JAK2 kinase inhibitors.

Search dates: October 2019 and January 2021.

The Authors

STEVEN FOX, MD, is an associate professor in the Department of Family Medicine and clerkship director at the University of Tennessee College of Medicine and assistant program director of the University of Tennessee Family Medicine Residency, Chattanooga.

LESLIE GRIFFIN, MD, is the program director of the University of Tennessee Family Medicine Residency and an assistant professor in the Department of Family Medicine at Erlanger Hospital and the University of Tennessee College of Medicine, Chattanooga.

DOMINIQUE ROBINSON HARRIS, MD, is a resident in the Department of Family Medicine at Erlanger Hospital and the University of Tennessee College of Medicine, Chattanooga.

Address correspondence to Steven Fox, MD, University of Tennessee College of Medicine, 1100 E 3rd St., Chattanooga, TN 37403 (email: steven.fox@erlanger.org). Reprints are not available from the authors.

References

1. Stuart BJ, Viera AJ. Polycythemia vera. *Am Fam Physician*. 2004;69(9):2139-2144. Accessed November 20, 2020. <https://www.aafp.org/afp/2004/0501/p2139.html>
2. Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis [published correction appears in *Am J Hematol*. 2015;90(9):850]. *Am J Hematol*. 2014; 89(6):581-587.
3. Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. *Eur J Haematol*. 2014; 92(4):289-297.
4. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*. 2014;124(16):2507-2513.
5. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. *Leukemia*. 2013;27(9): 1874-1881.
6. Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12 [published correction appears in *Br J Haematol*. 2017;177(2):331]. *Br J Haematol*. 2016;174(3): 382-396.
7. Pedersen KM, Bak M, Sørensen AL, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. *Cancer Med*. 2018;7(11):5796-5802.
8. Lindholm Sørensen A, Hasselbalch HC. Smoking and Philadelphia-negative chronic myeloproliferative neoplasms. *Eur J Haematol*. 2016;97(1):63-69.
9. Accurso V, Santoro M, Mancuso S, et al. Cardiovascular risk in essential thrombocythemia and polycythemia vera. *Mediterr J Hematol Infect Dis*. 2020;12(1):e2020008.
10. Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients [published correction appears in *Am J Hematol*. 2013;88(10):925]. *Am J Hematol*. 2013; 88(8):665-669.
11. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood*. 2011;118(2):401-408.
12. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2019;94(1):133-143.
13. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J*. 2018;8(2):15.
14. Essential Evidence Plus, Polycythemia vera. Wiley-Blackwell; 2020. Accessed November 21, 2020. <https://www.essentialevidenceplus.com/content/eee/274#accept>
15. Mesa R, Jamieson C, Bhatia R, et al. Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2016;14(12): 1572-1611.
16. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. *Blood Cancer J*. 2018;8(1):3.
17. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. *Blood*. 2012;119(15):3595-3603.
18. Marchioli R, Finazzi G, Specchia G, et al.; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med*. 2013; 368(1):22-33.
19. Podoltsev NA, Zhu M, Zeidan AM, et al. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. *Blood Adv*. 2018;2(20):2681-2690.
20. Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. *J Natl Compr Canc Netw*. 2017;15(10):1193-1207.
21. Landolfi R, Marchioli R, Kutti J, et al.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med*. 2004;350(2):114-124.
22. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. *Platelets*. 2006;17(8): 528-544.
23. Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. *Am J Hematol*. 2017; 92(11):1131-1136.
24. Ferrari A, Carobbio A, Masciulli A, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a sys-

POLYCYTHEMIA VERA

- tematic review and meta-analysis. *Haematologica*. 2019; 104(12):2391-2399.
25. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al.; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. *Br J Haematol*. 2016;172(5):786-793.
 26. Barbui T, Barosi G, Birgegard G, et al.; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol*. 2011;29(6):761-770.
 27. Kiladjian J-J, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. *Blood*. 2008;112(8):3065-3072.
 28. Douglas G, Harrison C, Forsyth C, et al. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. *Leuk Lymphoma*. 2017;58(1):89-95.
 29. Finazzi G, Caruso V, Marchioli R, et al.; ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood*. 2005;105(7):2664-2670.
 30. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *N Engl J Med*. 2015;372(5):426-435.
 31. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. *Br J Haematol*. 2001;115(3):619-621.
 32. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. *Blood*. 2002;99(7):2627.
 33. Pardanani A, Vannucchi AM, Passamonti F, et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. *Leukemia*. 2011;25(2):218-225.
 34. Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. *Br J Haematol*. 1995;89(2):313-318.
 35. Baldo A, Sammarco E, Plaitano R, et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. *Br J Dermatol*. 2002;147(5):979-981.
 36. McMullin MFF, Mead AJ, Ali S, et al. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology Guideline. *Br J Haematol*. 2019;184(2):161-175.
 37. Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. *Blood Rev*. 2008;22(5):235-245.
 38. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. *Leukemia*. 2010;24(9):1574-1579.
 39. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. *Arch Intern Med*. 2000; 160(7):939-944.
 40. Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. *Acta Med Scand*. 1962;172:513-523.
 41. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. *Blood Cancer J*. 2015;5(11):e366.